Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A3L24 extension booster study of Hexaxim versus Infanrix hexa in toddlers
2011-004428-36Phase 3
- Sponsor
- Sanofi
- Start
- Apr 2012
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in diphtheria, Tetanus, pertussis and 5 more comparing Hexaxim booster arm with Infanrix hexa booster arm (2 arms). Primary endpoint: Immunogenicity.
02
Drugs
hexaximpertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussispoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on 2011-004428-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004428-36.